

## **Member Profile**



**Alturus Biomedicine develops strategic solutions for Life Science companies. Alturus has worked with a broad range of companies from startups to major biopharmaceutical corporations both in the US and internationally.**

Alturus Biomedicine's Principal, Michael W. Long, PhD, and his associates have over 65 years of experience in Life Science R&D, Business, Marketing and Financial Projections. They've worked for and/or consulted with biopharmaceutical companies on projects as diverse as regenerative medicine, cell-based assay tools and small molecule development. Given the cutting-edge nature and potential of regenerative medicine, Alturus recognizes the need for help in this area and is specializing in its commercialization among our other activities. .

Regenerative Medicine is broadly defined as a multidisciplinary approach to restoring, or providing new tissues for damaged ones. It incorporates many, if not all, aspects of modern biomedical science to create and/or replace damaged tissues or organs. Examples of diseases that regenerative medicine can cure include diabetes, heart disease, renal failure, osteoporosis and spinal cord injuries. The current world market for replacement organ therapies is in excess of \$350 billion and the projected US market for regenerative medicine in 2025 is estimated at \$500 billion (US DHHS, "2020 Vision -- A Future for Regenerative Medicine").

### **Alturus' areas of expertise include:**

**Regenerative Medicine.** Alturus Biomedicine has extensive experience in regenerative medicine and its commercialization. Regenerative Medicine is broadly defined as a multidisciplinary approach to restoring, or providing new tissues for damaged ones. Perhaps the most important medical area of the 21<sup>st</sup> Century, Regenerative Medicine offers the potential to cure rather than treat most diseases.

**Stem Cells.** Alturus has experience in both academic research and commercial development of stem cells as therapies. Adult Stem Cells have been utilized for over 35 years in the form of bone marrow transplantation. Recent advances demonstrate that such cells can replace many adult tissues and over 2000 clinical trials are underway to test them.

**Drug Discovery & Development.** Our development experience covers the areas of: drug synthesis, lead identification/ optimization, in vivo and vitro efficacy, ADME, toxicity and preclinical animal studies. Alturus also has expertise in developing human cell-based platforms for both drug discovery and toxicity testing.

**Clinical Trials.** Alturus has overseen clinical trial planning in both human and veterinary medicine. Expertise includes site selection, CRO selection, trial design and FDA interactions (IND application and compliance).

**Economic Development.** Alturus has worked with regional and local governments to develop public-private partnerships. These were undertaken to co-develop high-tech job creation and develop regional strengths in translational medicine.